What is ImpediMed?
Founded in 1999 and headquartered in Queensland, Australia, ImpediMed has established itself as the global leader in the development and distribution of medical devices utilizing bioimpedance spectroscopy. The company's core technology provides clinicians with precise, non-invasive data regarding patient fluid status, a critical metric in managing chronic conditions and post-surgical recovery. By transforming complex physiological data into actionable clinical insights, ImpediMed occupies a vital niche in the healthcare technology landscape. Its commitment to rigorous scientific validation and technological innovation has allowed it to maintain a competitive edge, ensuring that its diagnostic solutions remain at the forefront of modern medical practice and patient-centric care models.
How much funding has ImpediMed raised?
ImpediMed has raised a total of $86.9M across 4 funding rounds:
Other Financing Round
$3.4M
Stock Offering
$11.5M
Share Placement
$57M
Other Financing Round
$15M
Other Financing Round (2006): $3.4M with participation from Starfish Ventures
Stock Issuance/Offering (2007): $11.5M, investors not publicly disclosed
Share Placement (2016): $57M, investors not publicly disclosed
Other Financing Round (2025): $15M featuring SWK Holdings and Armentum Partners
Key Investors in ImpediMed
Starfish Ventures
Starfish Ventures is a venture capital manager based in Australia, specializing in high growth technology businesses, particularly in information technology and life sciences.
SWK Holdings
SWK Holdings is a life science specialty finance company that provides innovative capital solutions to a broad range of life science companies, institutions, and inventors.
Armentum Partners
Armentum Partners is a full-service investment bank specializing in debt capital advisory services, primarily for technology and healthcare companies across North America, Europe, and Australia.
What's next for ImpediMed?
With the successful closure of this major enterprise-level funding, ImpediMed is well-positioned to accelerate its strategic growth initiatives. The company is expected to focus on expanding its global footprint, enhancing its product development pipeline, and deepening its penetration into key healthcare markets. By utilizing this capital to optimize its operational infrastructure and scale its commercial reach, ImpediMed aims to solidify its dominance in the BIS market. Future efforts will likely prioritize the integration of advanced data analytics into its existing device ecosystem, further empowering healthcare providers to deliver superior patient outcomes through enhanced diagnostic accuracy and streamlined clinical workflows.
See full ImpediMed company page
